Public Speaking Coach & Healthcare/Life Sciences Policy SME. Dr. Miller is a communications consultant with HealthPolCom Communications Consulting who helps individuals & organizations communicate the value of their products and services to achieve greater success. He is a Williams College alumni and a graduate of Yale School of Medicine.

Dr. Olin is an Associate professor in the Department of Pediatrics, Division of Hematology/Oncology at the University of Minnesota. Following 5 years in the Air Force, he graduated from the University of Minnesota, Duluth, in 1995 with a BS in biochemistry, Hydrogeology and a BA in chemistry.

Dr. Sina Bavari is the co-founder of Healion Bio. He is one of the lead (non-gov) scientific adviser to the World Health Organization on SARS CoV-2. He has spent over 30 years developing rapid response diagnostics, prophylaxis, therapeutics, and vaccines for some of the World’s deadliest infectious diseases.

Dr. Corey Casper is the Chief Executive Officer at the Infectious Disease Research Institute (IDRI). At IDRI, Dr. Casper oversees a scientific portfolio of vaccines, therapeutics, and diagnostics that provide comprehensive solutions to global health problems. These include impactful adjuvant formulations that enable 21st-century vaccines, a novel RNA replicon platform for the prevention of pandemic / emerging viruses, and a portfolio of products that aim to improve the treatment of cancer in low- and middle-income countries.

Dr. Gutierrez provides the scientific direction and business strategy for the Leidos Explorations in Global Health (ExGloH) Division which he co-founded in 2019. ExGloH is discovering and pre-clinically testing a novel class of peptide-based immuno-modulators for use not only in cancer but for safe application in infectious disease vaccines. Dr. Gutierrez has over 18 years of perience in vaccine development and cancer research. Dr. Gutierrez was Principal Investigator on two vaccine development contracts with the NIH and USAID (<$100M) from which five vaccines were successfully entered into Phase 1 clinical trials.

For the past thirty-one years, Dr. Steven Projan has been engaged in the discovery and development of novel drugs, mainly to treat and/or bacterial infections and other therapeutic areas. Dr. Projan has successfully led five programs resulting in the approval of novel anti-infective drugs with others in various stages of development with a shift towards prevention (in addition to treatment strategies). In the course of performing that applied research he has continued to be involved in more basic research programs studying microbial drug resistance, microbial virulence, biomarker discovery and development and epidemiology.

Division of Infectious Diseases and Immunology
Department of Pediatrics
University of Minnesota
McGuire Translational Research Facility

Mark R. Schleiss, MD, completed undergraduate studies in English Literature and Medical Microbiology at Stanford University in 1981, where he published his first paper on bacterial physiology and metabolism. After completion of the MD degree at Oregon Health Sciences University in 1985, he set off on a career in Pediatric medicine. After completion of his Pediatric internship and residency in 1988 (also at Oregon Health Sciences University and Doernbecher Children's Hospital), he commenced a Fellowship in Pediatric Infectious Diseases at Seattle Children's Hospital.